Nel

Carnegie Investment Bank is proud to have acted as Joint Bookrunner in Nel Hydrogen’s successful NOK 1.5 billion directed share issue.

Nel is experiencing ever-increasing interest and opportunities within the hydrogen industry and has more than doubled the addressable pipeline to USD 12 billion from the end of Q3-21 to the end of Q4-21. The company is committed to capitalizing on its position as a technology frontrunner and will continue to invest in building scale to develop the organization and the fueling, alkaline and PEM technology platforms. The net proceeds from the directed share issue will be used for continued investments in production capacity, organizational growth linked to order intake and tender activity, and general corporate purposes.

Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. Nel serves industries, energy, and gas companies with leading hydrogen technology. The company’s roots date back to 1927, and since then, they have had a proud history of development and continuous improvement of hydrogen technologies. Today, Nel’s solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles – without the emissions.

Carnegie congratulates Jon André LøkkeKjell Christian Bjørnsen and the rest of the Nel team with the successful transaction, and we look forward to continuing our support of Nel going forward.

Related articles

Schibsted
Investment Banking

Schibsted

Acquisition of 9.99% in FINN – NOK 2.5 billion Carnegie Investment Bank acted as financial advisor to...

BerGenBio ASA
Investment Banking

BerGenBio ASA

Carnegie Investment Bank is proud to have acted as manager in the exercise of warrants in...

Oncoinvent AS
Investment Banking

Oncoinvent AS

Carnegie Investment Bank is proud to have acted as Joint Bookrunner in connection with Oncoinvent AS’ NOK...